|Articles|June 28, 2016

Antibiotic-Resistant Bacteria Cause Multistate Outbreak

Author(s)Sarah Anwar

A multistate outbreak of Burkholderia cepacia infections might be linked to contaminated liquid docusate products in one of the states.

A multistate outbreak of Burkholderia cepacia infections might be linked to contaminated liquid docusate products in one of the states.

The Centers for Disease Control and Prevention (CDC) is conducting investigations regarding the outbreak in conjunction with the US Food and Drug Administration as well as state and local health departments and health facilities. The majority of the cases have been observed to be ventilated patients being treated in Intensive Care Units (ICU) who do not suffer from cystic fibrosis.

This is not the first outbreak caused by these bacteria. In 2004, several ICU patients in a Texas hospital were infected with B. cepacia; the infections were linked to exposure to contaminated sublingual probes. That same year a voluntary recall of over-the-counter nasal spray was issued due to contamination with the bacteria. The most recent outbreak was in 2005, when a multi-state outbreak of B. cepacia was linked to contaminated mouthwash. The patients developed several complications, including pneumonia.

According to the CDC, B. cepacia is a complex of gram-negative bacteria found in soil and water. Those at highest risk of developing severe complications from these generally antibiotic-resistant bacteria, are immunocompromised individuals, specifically those with chronic lung diseases, such as cystic fibrosis. Severity of B. cepacia infection varies among patients. While some patients are asymptomatic, others may develop serious respiratory infections.

B. cepacia can be transmitted through contact with an infected individual, contact with contaminated surfaces, through exposure to the bacteria’s natural environment, or through treatment with contaminated medicines or devices. Maintaining proper hand hygiene can reduce the risk of infection with B. cepacia.

The CDC advises against the use of liquid docusate products in patients with critical conditions, on ventilators, or who are immunosuppressed, until further information regarding the outbreak is known. Healthcare and laboratory personnel are urged to disclose all cases of B. cepacia infections in patients who do not have cystic fibrosis, to infection prevention staff, who should report the cases to state or local health authorities.


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.